Skip to main content
LPCN
NASDAQ Life Sciences

Lipocine CEO Mahesh Patel Buys 50,000 Shares for $79,488 Open-Market

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$1.69
Mkt Cap
$18.714M
52W Low
$1.36
52W High
$12.37
52W Position info
24% above low
Off High info
86% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

LPCN sits 24% above its 52-week low of $1.36 on light trading volume (0.1× avg).

Summary

Lipocine's CEO Mahesh Patel bought 50,000 shares on the open market for $79,487.50 at $1.58-$1.60 on November 12-13, raising his direct holdings to 211,495 shares. The purchase extends a run of insider accumulation that began with director purchases in early October.


Key Events · Ownership and Investor Activity · LPCN

  • CEO Open-Market Purchase

    Mahesh Patel bought 50,000 shares in two 25,000-share lots at $1.5796 and $1.5999 on 2026-11-12 and 2026-11-13, totaling $79,487.50.

  • Holdings Rise to 211,495 Shares

    Post-transaction direct ownership is 211,495 shares, up from 161,495 before the two purchases.

  • Third Insider Buy Since October

    Follows director John Higuchi's purchases of $27,132 on 2026-10-01 and $55,043 on 2026-10-02, bringing 90-day open-market insider buying to $82,174 with no sales.

  • Context: Approval and Cash Position

    Comes after Health Canada's 2026-10-07 approval of TLANDO and a Q3 with $2.3M revenue and $21.5M in cash and securities.


Analysis · LPCN · Life Sciences

The CEO put his own money into the stock across two days at $1.58-$1.60, lifting his direct stake to 211,495 shares. Modest in dollar terms for a nano-cap, but it marks the third insider open-market purchase in about six weeks and the first from the CEO himself, following director John Higuchi's buys on 2026-10-01 and 2026-10-02. Coming after the Health Canada TLANDO approval on 2026-10-07 and a Q3 with $2.3M of revenue and $21.5M in cash, the buying suggests management sees the current price as undervalued rather than as a liquidity need.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, LPCN was trading at $1.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.7M. The 52-week trading range was $1.36 to $12.37. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

LPCN - Latest Insights

LPCN
Nov 05, 2026, 9:30 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $1.47
Real-time Price: $1.74 info
Change: +$0.265 (+18%) info
Market Cap: $19.212M info
LPCN
Nov 05, 2026, 8:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $1.74 info
Change: +$0.285 (+20%) info
Market Cap: $19.212M info
LPCN
Oct 07, 2026, 6:10 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.16
Real-time Price: $1.74 info
Change: -$0.425 (-20%) info
Market Cap: $19.212M info
LPCN
Sep 14, 2026, 6:15 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.27
Real-time Price: $1.74 info
Change: -$0.535 (-24%) info
Market Cap: $19.212M info
LPCN
Aug 10, 2026, 7:37 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $2.13
Real-time Price: $1.74 info
Change: -$0.395 (-19%) info
Market Cap: $19.212M info